HST
49
-3
THC
70
-2
AON
23
-9
AXP
74
-3
AAL
32
-4
T
41
2
XOM
51
-9
DD
48
2
DO
58
6
LLY
56
2
VZ
30
3
TROW
58
10
SO
59
-3
PRGO
66
9
MSI
55
-3
HCA
35
-9
INTC
36
-5
MPC
52
10
ROK
46
3
LMT
55
-5
HST
49
-3
THC
70
-2
AON
23
-9
AXP
74
-3
AAL
32
-4
T
41
2
XOM
51
-9
DD
48
2
DO
58
6
LLY
56
2
VZ
30
3
TROW
58
10
SO
59
-3
PRGO
66
9
MSI
55
-3
HCA
35
-9
INTC
36
-5
MPC
52
10
ROK
46
3
LMT
55
-5
Financhill
Back

Intellia Therapeutics 10K Form

Sell
26

NTLA
Intellia Therapeutics

Last Price:
21.98
Seasonality Move:
34.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.28M
Cash Flow: $-94.57M
Price / Cash Flow: 0
Annual Sales: $11.29
Price / Book: 1.9

Profitability

EPS (TTM): -5.41000
Net Income (TTM): $-481.19M
Gross Margin: --
Return on Equity: -42.82%
Return on Assets: -35.35%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.67
Quick Ratio: 8.23

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
26
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?